Biogen’s SKYCLARYS becomes first approved treatment for Friedreich’s Ataxia in EU
In a landmark decision, the European Commission (EC) has authorized Biogen Inc.'s SKYCLARYS (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents ... Read More
Biogen to expand portfolio with $7.3bn acquisition of Reata Pharmaceuticals
Biogen Inc. (Nasdaq: BIIB) is set to acquire Reata Pharmaceuticals, Inc. (Nasdaq: RETA) for $172.5 per share in cash, amounting to an enterprise value of ... Read More
Reata Pharmaceuticals gets Skyclarys FDA approval for Friedreich’s Ataxia
Reata Pharmaceuticals has secured the approval of the US Food and Drug Administration (FDA) for Skyclarys (omaveloxolone) for the treatment of Friedreich’s ataxia, a neuromuscular ... Read More